The risk of diabetic kidney disease is not the same for everyone.
INNOVATIO-ND2 is a predictive test based on protein biomarkers. From one blood sample, it identifies up to 4 years in advance who will lose kidney function and how fast. eGFR and ACR show how the kidney is today; INNOVATIO-ND2 shows where it is heading.
CPT 0385U · Covered by Traditional Medicare, MCS (Advantage and commercial) and MMM (Advantage and Vital)
One test, three answers
A test that reads as predictive, not just diagnostic.
Is diabetic kidney disease already present?
A result above 30% indicates kidney disease is present, even when ACR and eGFR look normal.
Will eGFR fall by 30% or more?
Classifies the risk of an eGFR decline of 30% or more over the next 4 years as low, medium or high.
Fast or slow progression?
When kidney damage is present, it separates slow, medium and fast progressors without years of serial eGFR.
What each test tells you
| Test | Current kidney function | Future kidney function | Rate of decline |
|---|---|---|---|
| INNOVATIO-ND2 | Yes | Yes | Yes |
| Urine albumin-to-creatinine ratio (ACR) | Yes | No | No |
| Estimated glomerular filtration rate (eGFR) | Yes | No | No |
Information for everyone
How to read the result and act
Risk levels, recommended management, candidates and how to order.
Go to Physicians →Know your risk in time
What diabetic kidney disease is, how often to test and how to ask for it.
Go to Patients →Inside the assay
Assay type, algorithm variables, turnaround and availability.
Go to Laboratories →Where to get tested
56 laboratories in 32 towns in Puerto Rico have experience drawing the sample, plus every Laboratorios Borinquen branch.
